Continuous Glucose Monitoring in People Without Diabetes
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
A sensor worn on the arm for two weeks, streaming glucose readings to a phone. In type 1 diabetes this technology is transformative and the evidence is not in dispute. Sold to metabolically healthy adults as a way to discover which foods “spike” them, it is doing something quite different, and the evidence base is nowhere near the same place.
The underlying signal is real: Cichosz SL, Hejlesen O, et al. “From Stability to Variability: Classification of Healthy Individuals, Prediabetes, and Type 2 Diabetes Using Glycemic Variability Indices Derived From Continuous Glucose Monitoring.” Diabetes Technol Ther 2025;27:34–44 shows glucose variability metrics separate these groups measurably. What has not been shown is that a metabolically healthy adult who watches their post-meal curves ends up healthier than one who does not, or that excursions within the normal range carry prognostic meaning at all. Reference ranges for non-diabetic CGM metrics are still being established.
Cichosz SL, et al. Diabetes Technol Ther. 2025. PubMed: PMID 39115921
Singapore guidance
Not one of the named screening tests
Not among the tests Singapore’s national screening committee names for diabetes screening, which specifies fasting plasma glucose or HbA1c.
Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.
What you would actually pay
- Healthier SG
- Not subsidised
- MediSave
- Not among the screenings named for outpatient claims
Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.
What it costs when it is wrong
- Basis
- No published harm criterion found
- Severity
- Not documented
No published harm criterion found for this test.
An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.
Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.
FAQ
Is the Continuous Glucose Monitoring in People Without Diabetes worth doing in Singapore?
Continuous Glucose Monitoring in People Without Diabetes holds a emerging evidence grade under our screening rubric. It is most appropriate for unproven in metabolically healthy adults. Genuinely valuable in diabetes, and defensible as a one-off experiment rather than a diagnostic. It typically costs S$150–400 in Singapore. It is not established; typically sold as one or two 14-day sensor periods.
Weighing this against something else? Compare it with two other tests → · Price it inside a panel →